ORIGINAL ARTICLE: Mulligan, Casey B., The Value of Pharmacy Benefit Management (2022). University of Chicago, Becker Friedman Institute for Economics Working Paper No. 2022-93, Available at SSRN: http://dx.doi.org/10.2139/ssrn.4163025
Article Abstract: In theory, equilibrium profits for drug patent holders would not involve significant restraints on production and patient utilization if the market had a mechanism for two-part pricing (Oi 1971) or quantity commitments (Murphy, Snyder, and Topel 2014). In fact, patent expiration has little effect on drug utilization especially when those drugs are delivered through insurance plans. This paper provides a quantitative model consistent with the theory and evidence in which pharmacy benefit management on behalf of insurance plans serves these and other purposes in both monopoly and oligopoly provider settings. Calibrating the model to the U.S. market, I conclude that pharmacy benefit management is worth at least $145 billion annually beyond its resource costs. PBM services add at least $192 billion annually in value to society compared to a manufacturer price-control regime. Requiring all PBM services to be self-provided by plan sponsors would forgo about 40 percent of the net value of PBM services largely by increasing management costs. Due to changes in the incidence of PBM services over the drug life cycle, the services encourage innovation even though they reduce the profits of incumbent manufacturers.
Model description
In this model, the marginal cost of the drug is normalized to one. Consumers have preferences over the quantity
q
of a manufacturer’s drug and the quantity
Q
of sales by competitors, where
q
and
Q
are symmetric substitutes. With no income effects, demand functions that are linear in prices, and efficient quantities that are
q=Q=1
(a normalization of quantity units), the preferences must be those described by (up to the quasilinear term in expenditure on goods other than
q
and
Q
):
u(q,Q)=
1
η
(q+Q)(η-1)ϵ+(η+ϵ)qQ-ϵ
2
q
+
2
Q
2
η+ϵ
η-2ϵ
1+ϵ
where the constants
η
and
ϵ
satisfy
ϵ<η<0
and
ϵ<-1
. If consumers are allowed to purchase any amount of
q
and
Q
at prices
p
and
P
, respectively, their demand functions are:
q=
(ϵ+1)[ϵp+(η-ϵ)P]+(1-η)ϵ
η+ϵ
≡D(p,P)
and the symmetric demand function for
Q=D(P,p)
.
Setup and definitions
Economicreasoning.com is Casey Mulligan’s Wolfram Language package designed to infer user meaning from context, and to offer users push-button options for analysis. As a result, it can be used without user programming, and with just a minimal familiarity with the Wolfram language.